comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 14:18:15 - browse：85

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Stop Congress from blocking public access to science

Wikipedia

WSS

Mayo Clinic plans $5B tech

Organ aging and disease risk measured by new blood test

CDC picks Alphabet's Verily for wasterwater surveillance contract

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Health insurers' Q3 question: how much care are people getting?

With Roe v Wade overturned, abortion providers work to adapt

explore

comprehensive

hotspot

Activists slam private health insurers over coverage restrictions

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Peter Hotez and the public health issue of online harassment

CDC picks Alphabet's Verily for wasterwater surveillance contract

Malaria cases in Florida and Texas: Here’s what you need to know

Despite FDA concern, risk that CAR

Affirmative action in medical school literally saved lives

With Roe v Wade overturned, abortion providers work to adapt

New air purifier tech could be key to improving indoor air quality

Mayo Clinic plans $5B tech

entertainment

Medicare innovation center doesn’t save money, experts say

6 solutions to address cancer drug shortages and others

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Cigna, Humana reportedly in talks to merge

Flu, Covid vaccination rates decline, new survey data show

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

focus

Wikipedia

Wikipedia

leisure time